With TheraTears, Prestige Consumer Sees Way To Boost Guidance Despite COVID, Cost Uncertainties
Executive Summary
More than 17% growth in consumer health product sales in latest quarter on top of adding TheraTears brands to its lineup at start of current quarter outweighs potential headwinds from costs and changes in consumer spending, Prestige Consumer executives say.
You may also be interested in...
Prestige Consumer Healthcare Grows Global View
Overall revenues up 2.6% for October-December to $282.7m as, for second consecutive quarter, PCH reported international sales driving growth. International grew nearly 20% to $46.2m, while North America sales were down for second straight period.
Prestige Links Sales Growth To Retailer, Consumer Supply-Chain Fears
Retailer and consumer stockpiling in fear of supply chain disruptions drive double digit consumption growth for Prestige Consumer Healthcare’s Dramamine, Nix, Hydralyte and cough/cold brands. Brands drove total sales up 10.5% excluding impact of Akorn, to $12.4m in latest quarter.
US Q3 Consumer Health Earnings Preview: Helm Changes, Supply Challenges, Separation Plan
July-September results for sales of OTC drugs, supplements and personal care products will come with CEO leaving J&J and P&G, a new leader for Perrigo Americas, Bausch Health likely offering Bausch + Lomb separation details and a cloud of rising costs related to supplies.